PFE vs V: Which Is the Better Buy?

Side-by-side comparison of Pfizer Inc. and Visa Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-06-20.
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
VS
Visa Inc. · Financial Services
$327.24
+27.8% upside to fair value
Grade A High Quality
QuantHub Verdict
V has more upside to fair value (+27.8%). PFE trades at a lower forward P/E (19.2x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric PFE V
Current Price $25.22 $327.24
Fair Value Estimate $25.92 $418.15
Upside to Fair Value +2.8% +27.8%
Market Cap $143.7B $627.3B
Forward P/E 19.2x 28.2x
EV / EBITDA 12.3x 22.6x
Price / Sales 2.3x 14.6x
Price / FCF 15.2x 29.6x
Revenue Growth YoY +5.4% +17.1%
Gross Margin 69.3% 81.3%
Operating Margin 23.4% 61.1%
Return on Equity 8.4% 58.9%
Dividend Yield 0% 0%
FCF Yield 6.6% 3.38%
Analyst Consensus Hold Strong Buy
Investment Thesis
PFE — Pfizer Inc.
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
V — Visa Inc.
Visa Inc. operates a global payments network that facilitates electronic funds transfers worldwide, primarily through credit and debit cards. The company benefits from a very strong and widening moat driven by its extensive global card network and acceptance infrastructure, supported by a shareholder-friendly capital allocation policy including high buybacks and dividends. Visa's business quality…
Accumulation Zones
Metric PFE V
Zone Low $19.44 $313.61
Zone High $22.03 $355.43
In Buy Zone? No Yes
← PFE Research    V Research →    All Research